Intrepid Financial Planning Group LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Intrepid Financial Planning Group LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 18,345 shares of the biopharmaceutical company’s stock after selling 830 shares during the period. Intrepid Financial Planning Group LLC’s holdings in Pfizer were worth $531,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pfizer during the 1st quarter worth about $315,000. GSA Capital Partners LLP bought a new stake in Pfizer during the 1st quarter valued at about $439,000. Cozad Asset Management Inc. lifted its holdings in Pfizer by 12.9% during the 1st quarter. Cozad Asset Management Inc. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,216,000 after buying an additional 5,005 shares in the last quarter. Koshinski Asset Management Inc. raised its holdings in shares of Pfizer by 20.5% in the 1st quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock valued at $673,000 after purchasing an additional 4,130 shares in the last quarter. Finally, WP Advisors LLC raised its holdings in shares of Pfizer by 53.9% in the 1st quarter. WP Advisors LLC now owns 65,241 shares of the biopharmaceutical company’s stock valued at $1,810,000 after purchasing an additional 22,844 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 1.8 %

NYSE:PFE opened at $26.24 on Tuesday. The company has a market cap of $148.70 billion, a PE ratio of 35.46, a P/E/G ratio of 0.85 and a beta of 0.67. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average is $28.84 and its two-hundred day moving average is $28.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) EPS. Analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.40%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.